Repurposed drug may extend survival in aggressive ovarian cancer, trial shows
📖 Full Retelling
<p>Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases</p><p>A drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.</p><p>Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types becaus
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
<p>Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases</p><p>A drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.</p><p>Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types becaus
Read full article at source